gms | German Medical Science

16. Jahreskongress für Klinische Pharmakologie

Verbund Klinische Pharmakologie in Deutschland

09. - 10. Oktober 2014, Köln

Artikel

Artikel empfehlen

Valerian: No Clinically Relevant Interactions

Meeting Abstract

Suche in Medline nach

  • presenting/speaker O. Kelber - Steigerwald Arzneimittelwerk GmbH, Scientific Department – Darmstadt, Deutschland; Kooperation Phytopharmaka – Bonn, Deutschland
  • K. Kraft - Kooperation Phytopharmaka – Bonn, Deutschland; Universitätsmedizin Rostock, Lehrstuhl für Naturheilkunde – Rostock, Deutschland
  • K. Nieber - Kooperation Phytopharmaka – Bonn, Deutschland; Universität Leipzig, Pharmazeutisches Institut – Leipzig, Deutschland

16. Jahreskongress für Klinische Pharmakologie. Köln, 09.-10.10.2014. Düsseldorf: German Medical Science GMS Publishing House; 2014. Doc14vklipha41

doi: 10.3205/14vklipha41, urn:nbn:de:0183-14vklipha416

Veröffentlicht: 25. September 2014

© 2014 Kelber et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.

Gliederung

Text

Aim: In recent popular publications directed to cancer patients as well as in widely-used patient information websites (e. g. http://www.cancer.org/ or http://www.mskcc.org/) valerian is claimed to have a potential of adverse interactions with anti-cancer drugs, thereby questioning its widespread use as a safe replacement for benzodiazepines.

Method: A systematic review on the interaction potential of valerian preparations was conducted. Literature on Valeriana officinalis L. was retrieved by systematic data base search and by search in a clinical drug interaction data base (MedIQ).

Results: In several in vitro and in vivo animal studies on CYP 450 isoenzymes (CYP 450 1A2, 2D6, 2E1 and 3A4), p-glycoprotein and two uridine 5´-diphospho-glucuronosyltrans-ferase (UGT) isoenzymes (UGT) a rather weak interaction potential was shown. However, the methodological assessment of these studies does not support their suitability for the prediction of clinically relevant interactions. Clinical studies on CYP 450 1A2, 2D6, 2E1 and 3A4 and case reports did not reveal relevant interaction potentials of valerian root preparations.

Conclusion: The interaction potential of valerian preparations is low and unlikely to be clinically relevant, suggesting that their use is safe also in cancer patients.